Patents

Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.

Keywords:

Results 241 - 250 of 333

<< Previous | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Next >>

Last updated: 20th February 2008

Patents
Patent No.: US 6030789
Human conjunctival epithelial cell lines with an extended life span.
Applicant: Ward SL, Walker TL (2000)
The present invention provides two human conjunctival epithelial cell lines with an extended life span, designated HC0597 and HC0708, and methods for producing such cell lines. These conjunctival cell lines can be cultured as stratified 3-dimensional (3-D) cultures. In turn, the 3-D cultures can be used as tissue- and species-specific cellular models of the human conjunctival ocular surface. These human conjunctival cultures are particularly useful, for example, in product safety evaluations to test products for their eye irritation potential.

Patent No.: US 6025326
Compositions and methods for the prevention and treatment of oral mucositis.
Applicant: Steinberg DA, Chao DH, Loury DJ, Fu RC, Gu CL, Chang CC, Fiddes JC (2000)
The present invention provides methods and compositions suitable for treating oral mucositis in animals, including humans, with antimicrobial peptides such as protegrin peptides.

Patent No.: US 6022735
Composition for introducing nucleic acid complexes into higher eucaryotic cells.
Applicant: Curiel DT, Birnstiel ML, Cotten M, Wagner E, Zatloukal K, Plank C, Oberhauser B, Schmidt WGM (2000)
A composition for the transfection of higher eucaryotic cells, comprising complexes of nucleic acid, a substance having an affinity for nucleic acid and optionally an internalizing factor, contains an endosomolytic agent, e.g. a virus or virus component, which may be conjugated. The endosomolytic agent, which is optionally part of the nucleic acid complex, is internalized into the cells together with the complex and releases the contents of the endosomes into the cytoplasm, thereby increasing the gene transfer capacity. Pharmaceutical preparations, transfection kits and methods for introducing nucleic acid into higher eucaryotic cells by treating the cells with the composition are also disclosed.

Patent No.: US 6018103
Chimeric plant genes possessing independent regulatory sequences.
Applicant: Filipowicz W, Connelly S (2000)
The present invention relates to a chimeric gene construction comprising one promoter element and a 3' termination signal in functional combination with a gene, wherein a) the promoter is an snRNA promoter element from plants specific for RNA polymerase II b) promoter element, of signalling the formation of RNA 3' ends, c)the gene codes for a polypeptide for sense RNA, for anti-sense RNA or for snRNA, with the proviso that, in the case of the snRNA, the 3' termination signal used in b) represents a eukaryotic poly(A) signal.

Patent No.: US 6013638
Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung.
Applicant: Crystal RG, Dalemans W, Perricaudet M, Stratford-Perricaudet L, Pavirani A (2000)
The present invention relates, in general, to a adenovirus mediated transfer of genes to the lung. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of desired genes to the lung whereby desired proteins of interest are produced for local and/or systemic use.

Patent No.: US 6010908
Gene therapy by small fragment homologous replacement.
Applicant: Gruenert DC, Kunzelmann K (2000)
A method for gene therapy using small fragment homologous replacement. The method introduces small fragments of exogenous DNA into regions of endogenous genomic DNA virtually homologous to the exogenous DNA. The exogenous DNA fragments contains sequence modification that correct mutations in the endogenous DNA or introduce mutations that alter cellular or an infecting pathogen phenotype.

Patent No.: EP 979831
Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.
Applicant: Yamakawa M, Ishibashi J, Sakanaka H (2000)
Antibacterial peptides (X-Ala-Ile-Arg-Lys-Arg-NH2; X = 1 amino acid) derived from Oryctes rhinoceros and their formulations are described. Peptides are of high safety, improved activity, wide antibacterial spectrum, and low mol. wt. Due to low mol. wt., the effects of these peptides on immune system in vivo are decreased. The antibacterial peptides exhibited high antibacterial activity with min. inhibitory concn. (MIC) of 2-5 microg/mL against Staphylococcus aureus, 25-40 microg/mL against methicillin-resistant Staphylococcus aureus (MRSA), 4-10 microg/mL against Escherichia coli and 4->15 microg/mL against Pseudomonas aeruginosa. Toxicity of the peptides was tested in mice showing LD50 of > 150 mg/kg. A granule formulation was prepd. by mixing 500 mg the peptide with 50 mg of cryst. cellulose and 450 mg lactose, followed by blending together with 1 mL of an EtOH-H2O mixt. and granulation.

Patent No.: WO 9961468
Therapeutic induction of antibiotic proteins in the treatment of sepsis with derivatives of lactation-associated immunotrophic protein and soluble CD14.
Applicant: Julius MH, Filipp D (1999)
A method of ameliorating the symptoms of sepsis by exposing epithelial cells of a mammal to sol. CD14, or active sol. CD14 variants is described. A method of obtaining sol. CD14 from milk or colostrum, where it is known as LAIT (lactation-assocd. immunotropic protein) is described. The protein may be administered in food to stimulate defensin biosynthesis in the digestive tract. A method of directly activating B cells using a sol. polypeptide having the amino acid sequence: LLLLLLPS, LLLLLLPL, and LLLLLLVH recognized by the monoclonal antibody 3C10 and which activates B cells is described. The cattle gene for CD14 is also described.

Patent No.: WO 9949876
Bacterial or yeast extracts which stimulate the production of defensins and methods of use thereof.
Applicant: Mukerji P, Anderson GM, Kroening TA, Kirchner SJ, Zasloff MA, Fehlbaum P (1999)
The subject invention relates to exts. derived from, for example, a spent medium, a portion of a bacterial cell, a lysed yeast cell, or a portion of a lysed yeast cell which may be used to stimulate the prodn. of beta-defensins in eukaryotic cells such as, for example, mammalian cells. Furthermore, the present invention includes purified cell-free compns. contg. these exts. as well as methods of using these exts., for example, in the prevention and treatment of various disease states, in rehydration, and in the stimulation of the immune system. In an immortalized cell line pretreated with Lactobacillus acidophilus filtrate, beta-defensin mRNA was upregulated compared to untreated cells, as determined by quantitative reverse transcriptase PCR and capillary electrophoresis. Immunodeficient mice when pretreated with L. acidophilus filtrate and then orally challenged with Candida albicans showed reduced numbers of viable C. albicans as compared to the untreated control group.

Patent No.: WO 9949727
Antimicrobial protein compounds as novel oral hyperthermic agents for control of body weight and hypertension.
Applicant: Nasser JA, Lachance PA (1999)
Compns. for control of obesity and hypertension are disclosed. The active ingredient is a bacteriocin, e.g. nisin, which has been found to reduce body wt. by a mechanism of action also expected to be hypotensive. Methods for reducing body wt. and hypertension by ingesting the compns. of the invention are also disclosed.